The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") have opportunity to lead the securities fraud class ...
If you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to ...
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
The global placental growth factors market is poised for remarkable growth, with projections indicating a surge from USD 34.9 ...
Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...
When Morgan Stanley analyst Adam Jonas hosted a bull/bear lunch in New York recently to discuss Tesla investors wanted to talk about “anything but cars.” “After establishing that consensus is ...
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...
Pfizer named Dr Chris Boshoff as CSO and president of R&D, effective 1st January 2025. Boshoff, previously Pfizer’s chief ...
REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...
Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...
2-Year U.S. Treasury Note Continuous Contract $102.805 0.000 0.00% 5-Year U.S. Treasury Note Continuous Contract $106.250-0.016-0.01% 10-Year U.S. Treasury Note Continuous Contract $108.594-0.016 ...
Investor's Business Daily on MSN4h
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly ReviewThe stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback